



Access to Medicines

GHPF 20th March 2014

Comments on SANCO presentation

Where's the problem?

- * The EU has a clear objective in relation to Global Health
- * The analysis of barriers presented by SANCO is accurate without going into the relative significance of different factors
- * EU action across DG's is diffuse but extensive and influential – SANCO study is valuable as a bringing-together of the different strands

- * Population access to medicines is likely to improve further as a result of overall economic growth in emerging economies, creating greater domestic resources.
- * Although weak in many countries, the patient movement will become a voice for change
- * The UHC process will be critical to accelerating access (but will be heavily-influenced by domestic politics)

- * Pharmaceutical industry R&D investment is well-aligned with global healthcare needs, with certain specific exceptions (eg: PRND's, antibiotics) where new approaches are being established
- * To an increasing extent, companies understand that CSR is central to their business – more systematic approach to emerging country needs

Is this the problem?

- * EU influence over global health requires that the EU find a new alignment of its political, institutional, economic and industrial assets
 - * Better coordination is needed at every level
 - * Increased stakeholder involvement
 - * Rebalancing the relationship with key partners
- * The economic crisis has triggered doubts about the sustainability of the EU's own model, which is the basis of the global position
- * The UHC objective is very ambitious - needs to be matched by a multi-stakeholders and comprehensive approach
- * Acceptance of the health/growth linkage remains weak in the minds of many governments

Priorities from an industry perspective

- * Safety & Quality
- * Reduce counterfeits/emphasise need for high-quality sourcing
- * Accessibility
- * Promote health funding
- * Acceptability & appropriate use
- * Promote culture of patient health literacy
- * Affordability
- * Progress policy platform to support sustainable forms of price differentiation
- * Innovative financing/insurance models
- * Availability
- * Strengthen R&D funding and address market “failures”